Literatura ACTA MEDICINAE 5–7/2024 Gynekologie | Onkogynekologie | Urologie

Urgentní inkontinence moči u starších žen a její léčba

doc. MUDr. Petr Hubka, Ph.D. Gynekologicko-porodnická klinika, 1. LF UK a Fakultní nemocnice Bulovka, Praha

1 **Haylen, B. T. – de Ridder, D. – Freeman, R. M., et l.**: An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Int Urodynecol*, 2010, 21, s. 5–26.

2 **Nambiar, A. K. – Arlandis, S. – Bø, K., et al.**: European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence. *European Urology*, 2022, 82, s. 49–59.

3 **Yamada, S. – Ito, Y. – Nishijima, S., et al.**: Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. *Pharmacol Ther*, 2018, 189, s. 130–148.

4 **Dengler, K. L. – High, R. A. – Moga, D. C., et al.**: Overactive bladder and cognitive impairment: The American Urogynecologic Society and Pelvic Floor Disorders Research Foundation State-of-the-Science Conference Summary Report. *Urogynecology*, 2023, 29, suppl. 1, s. S1–S19.

5 **Mostafaei, H. – Salehi-Pourmehr, H. – Jilch, S., et al.**: Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: a systematic review and network meta-analysis. *Eur Urol Focus*, 2022, 8, s. 1072–1089.

6 **Risacher, S. L. – McDonald, B. C. – Tallman, E. F., et al.**: Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. *JAMA Neurol*, 2016, 73, s. 721–732.

7 **Chu, F. M. – Dmochowski, R.**: Pathophysiology of overactive bladder. *Am J Med*, 2006, 119, suppl. 1, s. 3–8.

8 **White, W. B. – Siddiqui, E. – Tat, T., et al.**: Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. *J Am Soc Hypertens*, 2018, 12, s. 768–778. e1.

9 **Wagg, A. – Staskin, D. – Engel, E., et al.**: Efficacy, safety, and tolerability of mirabegron in patients aged >/=65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). *Eur Urol*, 2020, 77, s. 211–220.

10 **Chapple, C. R. – Nazir, J. – Hakimi, Z., et al.**: Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. *Eur Urol*, 2017, 72, s. 389–399.

11 **Murray, B. – Miles-Thomas, J. – Park, A. J., et al.**: Cost-effectiveness of overactive bladder treatments from a US commercial and payer perspective. *J Comp Eff Res*, 2023, 12, e220089.

Léčba hyperaktivního měchýře

MUDr. Lukáš Holub, Ph.D. Urologická klinika LF a FN Hradec Králové

1 The Overactive Bladder: From Basic Science to Clinical Management Consensus Conference. Proceedings. Londýn, Anglie, 29. 6. 1997. *Urology*, 1997, 50, suppl. 6A, s. 1–114.

2 **Abrams, P. – Cardozo, L. – Fall, M., et al.**; Standardisation Sub-committee of the International Continence Society: The standardisation of terminology of lower urinary tract function: report from the Standar disation Sub-committee of the International Continence Society. *Neurourol Urodyn*, 2002, 21, s. 167–178.

3 **Willis-Gray, M. G. – Dieter, A. A. – Geller, E. J.**: Evaluation and management of over active bladder: strategies for optimizing care. *Res Rep Urol*, 2016, 8, s. 113–122.

4 **Blok, B., et al.**: EAU Guidelines on Neuro-urology. In: *EAU Guidelines Publisher dat the 38th EAU Annual Congress, Milan 2023*. Arnhem, Nizozemsko.

5 **Milsom, I. – Abrams, P. – Cardozo, L., et al.**: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. *BJU Int*, 2001, 87, s. 760–766.

6 **Irwin, D. E. – Milsom, I. – Hunskaar, S., et al.**: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *Eur Urol*, 2006, 50, s. 1306–1314; diskuze s. 1314–1315.

7 **Wein, A. J. – Rackley, R. R.**: Overactive bladder: a better understanding of pathophysiology, diagnosis and management. *J Urol*, 2006, 175, s. S5–S10.

8 **Brading, A. F.**: A myogenic basis for the overactive bladder. *Urology*, 1997, 50, suppl. 6A, s. 57–67; diskuze s. 68–73.

9 **de Groat, W. C.**: A neurologic basis for the overactive bladder. *Urology*, 1997, 50, suppl. 6A, s. 36–52; diskuze s. 53–56.

10 **Drake, M. J. – Mills, I. W. – Gillespie, J. I.**: Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. *Lancet*, 2001, 358, s. 401–403.

11 **Morrison, J. – Steers, W. D. – Brading, A. F., et al.**: Neurophysiology and neuropharmacology. In: Abrams, P. – Cardozo, L. – Khoury, S. – Wein, A. (eds.): *Incontinence*. Plymouth, Health Publications, 2002, s. 86–163.

12 **de Groat, W. C.**: The urothelium in overactive bladder: passive bystander or active participant? *Urology*, 2004, 64, 6 suppl. 1, s. 7–11.

13 **Andersson, K. E. – Hedlund, P.**: Pharmacologic perspective on the fysiology of the lower urinary tract. *Urology*, 2002, 60, 5 suppl. 1, s. 13–20; diskuze s. 20–21.

14 **Gevaert, T. – Vriens, J. – Segal, A., et al.**: Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. *J Clin Invest*, 2007, 117, s. 3453–3462.

15 **Abrams, P. – Andersson, K. E. – Birder, L., et al.**; Members of Committees; Fourth International Consultation on Incontinence: Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecalin continence. *Neurourol Urodyn*, 2010, 29, s. 213–240.

16 **Weiss, J. P. – Blaivas, J. G. – Bliwise, D. L., et al.**: The evaluation and treatment of nocturia: a consensus statement. *BJU Int*, 2011, 108, s. 6–21.

17 **Starkman, J. S. – Dmochowski, R. R.**: Urgency assessment in the evaluation of overactive bladder (OAB). *Neurourol Urodyn*, 2008, 27, s. 13–21.

18 **Foon, R. – Drake, M. J.**: The overactive bladder. *Ther Adv Urol*, 2010, 2, s. 147–155.

19 **Burgio, K. L.**: Influence of behavior modification on overactive bladder. *Urology*, 2002, 60, 5 suppl. 1, s. 72–76; diskuze s. 77.

20 **Krhut, J. – Holaňová, R. – Gärtner, M., et al.**: Fyzioterapie v léčbě inkontinence moči u žen. *Ces Urol*, 2015, 19, s. 131–136.

21 **Kunada, S. – Watanabe, N. – Goto, T., et al.**: Cognitive behavioral therapy for overactive bladder in women: study protokol for a randomized controlled trial. *BMC Urol*, 2020, 20, s. 129.

22 **Nitti, V. W – Patel, A. – Karram, M.**: Diagnosis and management of overactive bladder: A review. *J Obstet Gynaecol Res*, 2021, 47, s. 1654–1665.

23 **Shafik, A. – Shafik, I. A.**: Overactive bladder inhibition in response to pelvic floor muscle exercises. *World J Urol*, 2003, 20, s. 374–377.

24 **Shamliyan, T. – Wyman, J. – Kane, R. L.**: Non surgical treatments for urinary incontinence in adult women: diagnosis and comparative effectiveness. Rockville (MD): Agency for Health care Research and Quality (US); 2012. Report No.: 11(12)-EHC074-EF. PMID: 22624162.

25 **Alhasso, A. A. – McKinlay, J. – Patrick, K., et al.**: Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. *Cochrane Database Syst Rev*, 2006, 4, CD003193.

26 **Morrison, J. – Steers, W. D. – Brading, A. F., et al.**: Neurophysiology and neuropharmacology. In: Abrams, P. – Cardozo, L. – Khoury, S. – Wein, A. (eds.): *Incontinence*. Plymouth, Anglie, HealthPublications, 2002, s. 86–163.

27 **DuBeau, C. E.**: Interpreting the effect of common medical conditions on voiding dysfunction in the elderly. *Urol Clin North Am*, 1996, 23, s. 11–18.

28 **McKeage, K.**: Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor over activity, and in men with lower urinary tract symptoms. *Clin Drug Investig*, 2013, 33, s. 71–91.

29 **Zinner, N. R.**: Trospium chloride: an anticholinergic quaternary amonium compound for the treatment of overactive bladder. *Expert Opin Pharmacother*, 2005, 6, s. 1409–1420.

30 **Herschorn, S. – Swift, S. – Guan, Z., et al.**: Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. *BJU Int*, 2010, 105, s. 58–66.

31 **Chapple, C. R. – Araño, P. – Bosch, J. L., et al.**: Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. *BJU Int*, 2004, 93, s. 71–77.

32 **Chapple, C. R. – Martinez-Garcia, R. – Selvaggi, L., et al.**; STAR study group: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. *Eur Urol*, 2005, 48, s. 464–470.

33 **Cardozo, L. – Amarenco, G. – Pushkar, D., et al.**; SUNRISE Study Group: Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). *BJU Int*, 2013, 111, s. 804–810.

34 **Zinner, N. – Susset, J. – Gittelman, M., et al.**: Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. *Int J Clin Pract*, 2006, 60, s. 119–126.

35 **Chapple, C. R. – Kaplan, S. A. – Mitcheson, D., et al.**: Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. *Eur Urol*, 2013, 63, s. 296–305.

36 **Mullen, G. R. – Kaplan, S. A.**: Efficacy and safety of mirabegron in men with overactive bladder symptoms and benign prostatic hyperplasia. *Curr Urol Rep*, 2021, 22, s. 5.

37 **Staskin, D. – Frankel, J. – Varano, S., et al.**: International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. *J Urol*, 2020, 204, s. 316–324.

38 **Peters, D.**: Terodiline in the treatment of urinary frequency and motor urge incontinence. A controlled multicentre trial. *Scand J Urol Nephrol Suppl*, 1984, 87, s. 21–33.

39 **Mori, K. – Yamashita, Y. – Teramoto, N.**: Effects of ZD0947, a novel and potent ATP-sensitive K+ channel opener, on smooth muscle-type ATP-sensitive K+ channels. *Eur J Pharmacol*, 2016, 791, s. 773–779.

40 **Hunsballe, J. M. – Djurhuus, J. C.**: Clinical options for imipramine in the management of urinary incontinence. *Urol Res*, 2001, 29, s. 118–125.

41 **Buchbinder, R. – Forbes, A. – Kobben, F., et al.**: Clinical features of tiaprofenic acid (surgam) associated cystitis and a study of risk factors for its development. *J Clin Epidemiol*, 2000, 53, s. 1013–1019.

42 **Garnier, R. – Azoyan, P. – Chataigner, D., et al.**: Acute fluvoxamine poisoning. *J Int Med Res*, 1993, 21, s. 197–208.

43 **Thiagamoorthy, G. – Cardozo, L. – Robinson, D.**: Current and future pharmacotherapy for treating overactive bladder. *Expert Opin Pharmacother*, 2016, 17, s. 1317–1325.

44 **Biehl, C. – Plotsker, O. – Mirkin, S.**: A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. *Menopause*, 2019, 26, s. 431–453.

45 **Cheng, C. L. – Li, J. R. – Lin, C. H., et al.**: Positive association of female overactive bladder symptoms and estrogen deprivation: A nationwide population-based cohort study in Taiwan. *Medicine*, 2016, 95, s. e4107.

46 **Dykstra, D. D. – Sidi, A. A. – Scott, A. B., et al.**: Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. *J Urol*, 1988, 139, s. 919–922.

47 **Duthie, J. B. – Vincent, M. – Herbison, G. P., et al.**: Botulinum toxin injections for adults with overactive bladder syndrome. *Cochrane Database Syst Rev*, 2011, 12, CD005493.

48 **Nitti, V. W. – Dmochowski, R. – Herschorn, S., et al.**; EMBARK Study Group: OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. *J Urol*, 2013, 189, s. 2186–2193.

49 **Krhut, J.**: Workshop Místo botulinumtoxinu v terapii dysfunkcí dolních cest močových. *Ces Urol*, 2015, 19, s. 318–319

50 **Rejchrt, M.**: Využití neuromodulace v léčbě dysfunkcí dolních močových cest. *Ces Urol*, 2012, 16, s. 5–12.

51 **Amundsen, C. L. – Komesu, Y. M. – Chermansky, C., et al.**; Pelvic Floor Disorders Network: Two-year outcomes of sacral neuromodulation versus onabotulinumtoxin A for refractory urgency urinary incontinence: a randomized trial. *Eur Urol*, 2018, 74, s. 66–73.

52 **Jairam, R. – Drossaerts, J. – Marcelissen, T., et al.**: Predictive factors in sacral neuromodulation: a systematic review. *Urol Int*, 2022, 106, s. 323–343.

53 **Chughtai, B. – Clemens, J. Q. – Thomas, D., et al.**: Real world performance of sacral neuromodulation and onabotulinumtoxin A for overactive bladder: focus on safety and cost. *J Urol*, 2020, 203, s. 179–184.

54 **Greenwell, T. J. – Venn, S. N. – Mundy, A. R.**: Augmentation cystoplasty. *BJU Int*, 2001, 88, s. 511–525.

55 **Holub, L. – Hušek, P. – Košina, J., et al.**: Dopady změny antimuskarinika na kvalitu života u pacientů s hyperaktivním měchýřem – výsledky studie VEST. *Ces Urol*, 2018, 22, s. 106–114.

Když pacient odmítá invazivní léčbu: dlouhodobá kombinační medikamentózní terapie jako alternativa – kazuistika

MUDr. Barbora Novotná Urologické oddělení, Nemocnice České Budějovice, a. s.

1 **Lane, G. I. – Gor, R. A. – Katorski, J., et al.**: Clinical outcomes of non-surgical management of detrusor leak point pressures above 40 cm water in adults with congenital neurogenic bladder. *Neurourol Urodyn*, 2018, 37, s. 1943–1949.

2 **Kakizaki, H. – Lee, K. S. – Katou, D., et al.**: Mirabegron add-on therapy to tamsulosin in men with overactive bladder: post hoc analyses of efficacy from the MATCH study. *Adv Ther*, 2021, 38, s. 739–757.

3 **Shin, W. – Yang, A. Y. – Yoo, H., et al.**: Drug-drug interactions between tamsulosin and mirabegron in healthy individuals do not affect pharmacokinetics and hemodynamic parameters significantly. *Pharmaceuticals*, 2023, 16, s. 1457.

4 **Gratzke, C. – van Maanen, R. – Chapple, C., et al.**: Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). *Eur Urol*, 2018, 74, s. 501–509.

5 **Herschorn, S. – Chapple, C. R. – Abrams, P., et al.**: Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). *BJU Int*, 2017, 120, s. 562–575.

Současné možnosti léčby karcinomu ledviny

MUDr. Jiří Kolář, Ph.D. | MUDr. Petr Stránský jr. | prof. MUDr. Milan Hora, Ph.D., MBA Urologická klinika, LF UK a FN Plzeň
doc. MUDr. Ondřej Fiala, Ph.D. Onkologická a radioterapeutická klinika, LF UK a FN Plzeň
doc. MUDr. Kristýna Pivovarčíková, Ph.D. Šiklův ústav patologie, LF UK a FN Plzeň

1 **Padala, S. A. – Barsouk, A. – Thandra, K. C., et al.**: Epidemiology of renal cell carcinoma. *World J Oncol*, 2020, 11, s. 79–87.

2 **Sung, H. – Ferlay, J. – Siegel, R. L., et al.**: Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*, 2021, 71, s. 209–249.

3 **Dušek, L. – Mužík, J. – Kubásek, M., et al.**: *Epidemiologie zhoubných nádorů v České republice*. Masarykova univerzita, Brno, 2022.

4 **Capitanio, U. – Bensalah, K. – Bex, A., et al.**: Epidemiology of renal cell carcinoma. *Eur Urol*, 2019, 75, s. 74–84.

5 **Kolář, J. – Pitra, T. – Pivovarčíková, K., et al.**: Hereditární renální nádorové syndromy. *Ces Urol*, 2020, 24, s. 26–41.

6 **Bekema, H. J. – MacLennan, S. – Imamura, M., et al.**: Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma. *Eur Urol*, 2013, 64, s. 799–810.

7 **Lane, B. R. – Tiong, H. Y. – Campbell, S. C., et al.**: Management of the adrenal gland during partial nephrectomy. *J Urol*, 2009, 181, s. 2430–2436; diskuze 6–7.

8 **Korčáková, E., et al.**: Mikrovlnná ablace a její role v léčbě malých renálních nádorů. *Ces Urol*, 2023, 27, s. 213–221.

9 **Kolář, J. – Pitra, T. – Pivovarčíková, K., et al.**: Biopsie nádorů ledvin – indikace, provedení, výsledky. *Ces Urol*, 2020, 24, s. 2113–2125.

10 **Lane, B. R. – Abouassaly, R. – Gao, T., et al.**: Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. *Cancer*, 2010, 116, s. 3119–3126.

11 **Jewett, M. A. – Mattar, K. – Basiuk, J., et al.**: Active surveillance of small renal masses: progression patterns of early stage kidney cancer. *Eur Urol*, 2011, 60, s. 39–44.

12 **Choueiri, T. K. – Tomczak, P. – Park, S. H., et al.**: Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. *N Engl J Med*, 2021, 385, s. 683–694.

13 **Nesbitt, J. C. – Soltero, E. R. – Dinney, C. P., et al.**: Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. *Ann Thorac Surg*, 1997, 63, s. 1592–1600.

14 **Büchler, T.**: Karcinom ledviny a jeho léčba. *Postgraduální nefrologie*, 2020, 18, s. 8–10.

15 Zhoubný novotvar ledviny (C64). Modrá kniha České onkologické společnosti. 30. aktualizace. MOÚ Brno, 2024. Platnost od 1. 3. 2024. Dostupné z: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/, vyhledáno 10. 4. 2024.

16 **Ljungberg, B. – Albiges, L. – Abu-Ghanem, Y., et al.**: European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. *Eur Urol*, 2022, 82, s. 399–410.

17 **Heng, D. Y. – Xie, W. – Regan, M. M., et al.**: External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. *Lancet Oncol*, 2013, 14, s. 141–148.

Imunoterapie v léčbě gynekologických malignit

prof. MUDr. Michal Zikán, Ph.D. Gynekologicko-porodnická klinika, 1. LF UK a Fakultní nemocnice Bulovka, Praha

1 **Kagabu, M. – Nagasawa, T. – Sato, C. – Fukagawa, Y., et al.**: Immunotherapy for uterine cervical cancer using checkpoint inhibitors: future directions. *Int J Mol Sci*, 2020, 21, s. 2335.

2 **Peralta-Zaragoza, O. – Bermúdez-Morales, V. H. – Perez-Plasencia, C., et al.**: Targeted treatments for cervical cancer: a review. *Onco Targets and Therapy*, 2012, 5, s. 315–328.

3 **Jazaeri, A. A. – Zsiros, E. – Amaria, R. N., et al.**: Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. *J Clin Oncol*, 2019, 37, suppl. 15, s. 2538–2538.

4 **Eskander, R. N. – Tewari, K. S.**: Immunotherapy: an evolving paradigm in the treatment of advanced cervical cancer. *Clin Ther*, 2015, 37, s. 20–38.

5 **Enwere, E. K. – Kornaga, E. N. – Dean, M., et al.**: Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. *Mod Pathol*, 2017, 30, s. 577–586.

6 **Browne, D. W. – Fennelly, J. – Crown, H., et al.**: The efficacy and safety of pembrolizumab in advanced cervical cancer—a real world treatment study in an Irish healthcare setting. *J Clin Oncol*, 2020, 38, suppl. 15, s. e18007–e18007.

7 **da Silva, D. M. – Enserro, D. M. – Mayadev, J. S., et al.**: Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929). *Clinical Cancer Research*, 2021, 26, s. 5621–5630.

8 **Naumann, R. W. – Oaknin, A. – Meyer, T., et al.**: Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: results from Check Mate 358. *Ann Oncol*, 2019, 30, suppl. 5, LBA62.

9 **Tewari, K. S. – Monk, B. J. – Vergote, I., et al.**: VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma. *Ann Oncol*, 2021, 32, s. 940–941.

10 **O'Malley, D. M. – Oaknin, A. – Monk, B. J., et al.**: Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials. *Ann Oncol*, 2020, 31, suppl. 4, s. S1164–S1165.

11 **O'Malley, D. – Neffa, M. – Monk, B. J., et al.**: 724MO Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4): Final results from a phase II study in patients (pts) with recurrent/metastatic (R/M) cervical cancer (CC). *Ann Oncol*, 2021, 32, s. S727.

12 **Colombo, N. – Dubot, C. – Lorusso, D., et al.**: LBA2 Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study. *Ann Oncol*, 2021, 32, s. S1307–S1308.

13 **Song, Y. –Wang, C. – Li, X., et al.**: 782P A retrospective study of toripalimab combined with concurrent chemoradiotherapy in patients with recurrent/advanced cervical cancer. *Ann Oncol*, 2021, 32, s. S755.

14 **Frenel, J. S. – Hervieu, A. – Borcoman, E., et al.**: 775P Tremelimumab (T)+ durvalumab (D) combined with metronomic oral vinorelbine (MOV): Results of the recurrent cervical cancer (RCC) cohort of the MOVIE study. *Ann Oncol*, 2021, 32, s. S753.

15 **Youn, J. W. – Hur, S. Y. –Woo, J. W., et al.**: Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: Interim results of a single-arm, phase 2 trial. *Lancet Oncol*, 2020, 21, s. 1653–1660.

16 **Concin, N. – Matias-Guiu, X. – Vergote, I., et al.**: ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. *Int J Gynecol Cancer*, 2021, 31 , s. 12–39.

17 **Humber, C. E. – Tierney, J. F. – Symonds, R. P., et al.**: Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. *Ann Oncol*, 2007, 18, s. 409–240.

18 **Fleming, G. F.**: Second-line therapy for endometrial cancer: the need for better options. *J Clin Oncol*, 2015, 33, s. 3535–3540.

19 **Levine, D. A.**: Integrated genomic characterization of endometrial carcinoma. *Nature*, 2013, 497, s. 67–73.

20 **Marcus, L. – Lemery, S. J. – Keegan, P., et al.**: FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors. *Clin Cancer Res*, 2019, 25, s. 3753–3758.

21 FDA grants regular approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma. Dostupné z: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pembrolizumab-and-lenvatinib-advanced-endometrial-carcinoma, vyhledáno 11. 4. 2024.

22 **Marabelle, A. – Le, D. T. – Ascierto, P. A., et al.**: Efficacy of pembrolizumab in patientswith noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. *J Clin Oncol*, 2020, 38, s. 1–10.

23 **Le, D. T. – Durham, J. N. – Smith, K. N., et al.**: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science*, 2017, 357, s. 409–413.

24 **Fader, A. N. – Diaz, L. A. – Armstrong, D. K., et al.**: Preliminary results of a phase II study: PD-1 blockade in mismatch repair–deficient, recurrent or persistent endometrial cancer. *Gynecol Oncol*, 2016, 141, s. 206–207.

25 **Roque, D. M. – Bellone, S. – Siegel, E. R., et al.**: Phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). *J Clin Oncol*, 2021, 39, s. 5523–5523.

26 **Ott, P. A. – Bang, Y.-J. – Berton-Rigaud, D., et al.**: Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. *J Clin Oncol*, 2017, 35, s. 2535–2541.

27 **Makker, V. – Taylor, M. H. – Aghajanian, C., et al.**: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. *J Clin Oncol*, 2020, 38, s. 2981–2992.

28 **Makker, V. – Colombo, N. – Casado Herráez, A., et al.**: Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women's Cancer. A multicenter, open-label, randomized phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer: study 309/KEYNOTE-775. *Int J Gynec Canc*, 2021, 31, s. A4–5.

29 Tamura, K. – Hasegawa, K. – Katsumata, N., et al.: Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. *Cancer Sci*, 2019, 110, s. 2894–2904.

30 **Lheureux, S. – Matei, D. – Konstantinopoulos, P. A., et al.**: A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. *J Clin Oncol*, 2020, 38, suppl. 15, doi.org/10.1200/JCO.2020.38.15_suppl.6010.

31 **Oaknin, A. – Duska, L. R. – Sullivan, R. J., et al.**: Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H and MSS endometrial cancer. *Gynecol Oncol*, 2019, 154, s. 17.

32 **Mirza, M. R., et al.**: Dostarlimab for primary advanced or recurrent endometrial cancer. *N Engl J Med*, 2023, 388, s. 2145–2158.

33 **Eskander, R. N. – Sill, M. W. – Beffa, L., et al.**: Pembrolizumab plus chemotherapy in advanced endometrial cancer. *N Engl J Med*, 2023, 388, s. 2159–2170.

Telomeropatie – vzácný, ale podceňovaný problém v reprodukční medicíně – přehledový článek a kazuistika

MUDr. Radka Jarošová Gennet – klinika reprodukční medicíny a genetiky, Praha, Clayo Clinic – klinika reprodukční medicíny, Praha
PharmDr. Lucie Slámová Gennet – klinika reprodukční medicíny a genetiky, Praha, Ústav hematologie a krevní transfuze, Praha
RNDr. Monika Beličková, Ph.D. Ústav hematologie a krevní transfuze, Praha
MUDr. David Stejskal Gennet – klinika reprodukční medicíny a genetiky, Praha

1 **Niewisch, M. R. – Savage, S. A.**: An update on the biology and management of dyskeratosis congenita and related telomere biology disorders. *Expert Rev Hematol*, 2019, 12, s. 1037–1052.
2 **Turner, K. J. – Vasu, V. – Griffin, D. K.**: Telomere biology and human-phenotype. *Cells*, 2019, 8, s. 73.
3 **Giardini, M. A. – Segatto, M. – da Silva, M. S., et al.**: Telomere and telomerase biology. *Prog Mol Biol Transl Sci*, 2014, 125, s. 1–40.
4 **Penzo, M. – Ludovini, V. – Treré, D., et al.**: Dyskerin and TERC expression may condition survival in lung cancer patients. *Oncotarget*, 2015, 6, s. 21755–21760.
5 **Conomos, D. – Pickett, H. A. – Reddel, R. R.**: Alternative lengthening of telomeres: remodeling the telomere architecture. *Front Oncol*, 2013, s. 27.
6 **Calado, R. T. – Yewdell, W. T. – Wilkerson, K. L., et al.**: Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoetic cells. *Blood*, 2009, 114, s. 2236 –2243.
7 **Robinson, L. G. Jr. – Pimentel, R. – Wang, F., et al.**: Impaired reproductive function and fertility preservation in a woman with a dyskeratosis congenita. *J Assist Reprod Genet*, 2020, 37, s. 1221–1225.
8 **Koucký, M. – Toman, A. – Ryšavá, R., et al.**: Trombotické mikroangiopatie a těhotenství. *Ceska Gynekol*, 2020, 85, s. 18–28.
9 **Giri, N. – Alter, P. – Savage, A., et al.**: Gynecological and reproductive health of woman with telomere biology disorders. *Br J Haematol*, 2021, 193, s. 1238–1242.
10 ACOG. ACOG Practice Bulletin No. 202: gestational hypertension and preeclampsia. *Obstet Gynecol*, 2019, 133, s. 1.
11 **Jeve, Y. B. – Davies, W.**: Evidence-based management of recurrent miscarriages. *J Hum Reprod Sci*, 2014, 7, s. 159–169.
12 **Ananth, C. V. – Friedman, A. M. – Keyes, K. M., et al.**: Primary and repeat Cesarean deliveries: a population-based study in the US, 1979–2010. *Epidemiology*, 2017, 28, s. 567–574.
13 **Bateman, B. T. – Shaw, K. M. – Kuklina, E. V., et al.**: Hypertension in women of reproductive age in the US, NHANES 1999–2008. *PloS One*, 2012, 7, e36171.
14 **Workalehamu, T. – Enquobahrie, D. A. – Yohannes, E., et al.**: Placental telomere length and risk of placental abruption. *J Matern Fetal Neonatal Med*, 2016, 29, s. 2767–2772.
15 **Deka, D. – Malhotra, N. – Sinha, A., et al.**: Pregnancy associated aplastic anemia: maternal and fetal outcome. *J Obstet Gynaecol Res*, 2003, 29, s. 67–72
16 **Tichelli, A. – Socie, G. – March, J., et al.**: Outcome of pregnancy and disease course among woman with aplastic anemia treated with immunosuppression. *Ann Intern Med*, 2002, 137, s. 164–172.
17 **Hapangama, D. K. – Kamal, A. – Saretzki, G.**: Implications of telomeres and telomerase in endometrial pathology. *Hum Reprod Update*, 2017, 23, s. 166–187.
18 **Vieri, M. – Brümmendorf, T. M. – Fabian Beier, F.**: Treatment of telomeropathies. *Best Pract Res Clin Haematol*, 2021, 34, 101282.
19 **Bejarano, L. – Bosso, G. – Louzame, J., et al.**: Multiple cancer pathways regulate telomere protection. *EMBO Mol Med*, 2019, 11, e10292.

Preventivní gynekologická prohlídka – je to, co děláme, skutečně praktické a k užitku?

MUDr. Štěpán Budka GYO, s. r. o., ambulance gynekologie a porodnictví, gynekologie dětí a dospívajících, reprodukční medicíny a estetické gynekologie
MUDr. Miroslav Verner PorGys, s. r. o., ambulance gynekologie a porodnictví

1 Sbírka zákonů č. 3 /2010, vyhláška ze dne 17. prosince 2009, o stanovení obsahu a časového rozmezí preventivních prohlídek, částka 1, strana 10, § 4: Obsah a časové rozmezí preventivních prohlídek v oboru gynekologie a porodnictví.
2 Vyhláška č. 70/2012 Sb., o preventivních prohlídkách, ve znění pozdějších předpisů.
3 Vyhláška č. 45/2021 Sb., kterou se mění vyhláška č. 70/2012 Sb., o preventivních prohlídkách, ve znění pozdějších předpisů.
4 Věstník MZ ČR 2007, částka 7, vydáno v září 2007: Kritéria a podmínky programu pro screening karcinomu děložního hrdla v ČR.
5 Evaluační zpráva programu screeningu karcinomu děložního hrdla, NSC ÚZIS, 2022. Dostupné z: https://nsc.uzis.cz/res/file/vystupy/datova-zakladna/evaluacni-zprava-screeningu-cervikalniho-karcinomu.pdf, vyhledáno 20. 5. 2024.
6 Doporučení k testování BRCA1/BRCA2 a dalších genů pro účely léčby schválené 7. září 2022 výborem Společnosti lékařské genetiky a genomiky ČLS JEP. Dostupné z: https://slg.cz/doporuceni/, vyhledáno 20. 5. 2024.
7 Registr CZECANCA, www.czecanca.cz.
8 **Devries, K. M. – Mak, J. Y. T. – García-Moreno, C., et al.**: The global prevalence of intimate partner violence against women. *Science*, 2013, doi: 10.1126/science.1240937.
9 **Vaníčková, E. – Hanáček, J. – Krpálková, J., et al.**: *Domácí a genderově podmíněné násilí. Manuál pro lékaře*. 2017. Dostupné z: https://urgmed.cz/wp-content/uploads/2019/03/2018_manual_nasili.pdf, vyhledáno 20. 5. 2024.
10 **Norrell, L. L. – Kuppmermann, M. – Moghadassi, M. N., et al.**: Women's beliefs about the purpose and value of routine pelvic examinations. *Am J Obstet Gynecol*, 2017, 217, s- 86.e1–86.e6.
11 **Dempsey, A. F., et al.**: Acceptability of human papillomavirus vaccines among women older than 26 years. *Vaccine*, 2015, 33, s. 1556–1561.
12 **Castellsagué, X. – Schneider, A., et al.**: HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. *Gynecol Oncol*, 2009, 115, suppl. 3, s. S15–S23.
13 NRRZ, www.uzis.cz.
14 ÚZIS, www.uzis.cz.
15 **Varlas, V. N., et al.**: Social freezing: pressing pause on fertility. *Int J Environ Res Public Health*, 2021, 18, s. 8088.
16 **Balderrama, C. – Flores, J. – Maldonado, A.**: The effects of age to meet the standard production rate. *Work*, 2015, 51, s. 827–837.
17 **Fauser, B. C. J. M. – Nelson, S. M.**: Next steps toward AMH as a robust biomarker for assessing ovarian aging in individual women. *J Clin Endocrinol Metab*, 2020, 105, s. e2643–e2644..
18 **Abed, F. A. – Maroof, R. E. – Al-Nakkash, U. M. A.**: Comparing the diagnostic accuracy of anti-Müllerian hormone and follicle stimulating hormone in detecting premature ovarian failure in iraqi women by ROC analysis. *Rep Biochem Mol Biol*, 2019, 8, s. 126–131.

Reprodukční imunologie

MUDr. Barbora Koubková Oddělení alergologie a klinické imunologie, Fakultní nemocnice Olomouc

1 **Malíčková, K. – Ambrusová, Z. – Belvončíková, S., et al.**: Současné možnosti diagnostiky a léčby imunologických příčin ženské neplodnosti. *Čas Lék Čes*, 2021, 160.
2 **Řežábek, K. – Pohlová, R.**: Asistovaná reprodukce v ČR 2020. Zdravotnická statistika. Ústav zdravotnických informací a statistiky ČR ve spolupráci s Národním registrem reprodukčního zdraví – Asistované reprodukce. ÚZIS ČR, NRAR 2022, s. 1–71. www.uzis.cz
3 **Ulčová-Gallová, Z. – Madar, J.,et al.**: *Imunologie a imunopatologie lidské reprodukce*. Maxdorf Jessenius, Praha, 2020, s. 176.
4 **Řezáčová, J., et al.**: *Reprodukční medicína. Současné možnosti v asistované reprodukci*. Mladá fronta, Praha, 2018, s. 710.
5 **Kwak-Kim, J.**: T cell immunopathology in women with reproductive failures; causes and treatment. *J Reproductive Immunology*, 2023, 159, 104013, doi.org/10.1016/j.jri.2023.104013.
6 **Hao, F. – Zhou, X. – Jin, L.**: Natural killer cells: functional differences in recurrent spontaneous abortion. *Biol Reprod*, 2020, 102, s. 524–531.
7 **Koucký, M.**: Péče o těhotnou ženu s opakovanými těhotenskými ztrátami a prokázaným imunodeficitem z pohledu porodníka. *Čas Lék Čes*, 2021, 160, s. 14–19.
8 **Dodd, J. M. – MacLeod, A. – Windrim, R. C., et al.**: Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. *Cochrane Database Syst Rev*, 2013, CD006780.

Deficit železa a jeho vliv na sexuální dysfunkce u žen

MUDr. Marek Broul, Ph.D., MBA, FECSM Sexuologické oddělení, Krajská zdravotní, a. s. – Masarykova nemocnice v Ústí nad Labem, o. z.; Urologické oddělení, Krajská zdravotní, a. s. – Nemocnice Litoměřice, o. z.; Fakulta zdravotnických studií Univerzity Jana Evangelisty Purkyně

1 **Pastor, Z.**: Jak správně klasifikovat ženské sexuální dysfunkce? *Prakt Gyn*, 2015, 19, s. 60–65.
2 ICD-10 Version: 2019. Dostupné z: https://icd.who.int/browse10/2019/en.
3 ČR, ÚZIS. MKN-10 klasifikace. Dostupné z: https://mkn10.uzis.cz/.
4 MKN-11. Dostupné z: https://www.uzis.cz/ext/mkn-11-nahled/.
5 **Montorsi, F. – Pierce, C. J. – Khoury, S.**: The Third International Consultation on Sexual Medicine: Advancing Science in the Interest of Patient Care. *J Sex Med*, 2010, 7, s. 312–313.
6 Diagnostic and Statistical Manual of Mental Disorders. DSM-5. American Psychiatric Association. Diagnostic and Statiscital manual of mental disorders, Firth Edition. Dostupné z: https://doi.org/10.1176/appi.books.9780890425596.
7 **Koops, T. U. – Klein, V. – Bei der Kellen, R. – Hoyer, J., et al.**: Association of sexual dysfunction according to DSM-5 diagnostic criteria with avoidance of and discomfort during sex in a population-based sample. *Sex Med*, 2023, 11, qfad037.
8 **Basson, R.**: The female sexual response: a different model. *J Sex Marital Ther*, 2000, 26, s. 51–65.
9 **Nappi, R. E. – Cucinella, L. – Martella, S., et al.**: Female sexual dysfunction (FSD): Prevalence and impact on quality of life (QoL). *Maturitas*,

2016, 94, s. 87–91.
10 American Psychiatric Association, ed.: Diagnostic and statistical manual of mental disorders (DSM-5-TR). Dostupné z: https://www.psychiatry.org/psychiatrists/practice/dsm.
11 **Shifren, J. L. – Monz, B. U. – Russo, P. A., et al.**: Sexual problems and distress in United States women: prevalence and correlates. *Obstet Gynecol*, 2008, 112, s. 970–978.
12 **Zheng, J. M. – Skiba, A. – Bell, R. J., et al.**: The prevalence of sexual dysfunctions and sexually related distress in young women: a cross-sectional survey. *Fertil Steril*, 2020, 113, s. 426–434.
13 **Friedman, A. J. – Chen, Z. – Ford, P., et al.**: Iron deficiency anemia in women across the life span. *J Womens Health*, 2012, 21, s. 1282–1289.
14 **Hartmann, C. J. – Sutter, B. – Fehr, M., et al.**: Impact of body iron store on sexual function: a comprehensive review and pilot cohort study in midlife women. *Arch Gynecol Obstet*, 2019, 300, s. 469–480.
15 **Serati, M. – Espuña-Pons, M. – Mouton-Puglisi, A., et al.**: Iron deficiency and sexual dysfunction in women. *Sex Med Rev*, 2023, 11, s. 342–348.
16 **Pasricha, S.-R. – Tye-Din, J. – U Muckenthaler, M., et al.**: Iron deficiency. *Lancet*, 2021, 397, s. 233–248.
17 **Percy, L. – Mansour, D. – Fraser, I.**: Iron deficiency and iron deficiency anaemia in women. *Best Pract Res Clin Obstet Gynaecol*, 2017, 40, s. 55–67.
18 **Liu, Z. – Doan, Q. V. – Blumenthal, P., et al.**: A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. *Value Health*, 2007, 10, s. 183–194.
19 **Calje, E. – Marriott, J. – Oyston, Ch., et al.**: Postpartum anaemia in three New Zealand district health board regions: An observational study of incidence and management. *Aust N Z J Obstet Gynaecol*, 18. 7. 2022.
20 **Næss-Andresen, M.-L. – Jenum, A. K. – Berg, J. P., et al.**: Prevalence of postpartum anaemia and iron deficiency by serum ferritin, soluble transferrin receptor and total body iron, and associations with ethnicity and clinical factors: a Norwegian population-based cohort study. *J Nutr Sci*, 2022, 11, s. e46.
21 **Leiblum, S. R. – Koochaki, P. E. – Rodenberg, C. A., et al.**: Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). *Menopause*, 2006, 13, s. 46–56.
22 **Nikzad, Z. – Iravani, M. – Abedi, P., et al.**: The relationship between iron deficiency anemia and sexual function and satisfaction among reproductive-aged Iranian women. *PLOS ONE*, 2018, 13, s. e0208485.
23 **Erikson, K. M. – Jonec, B. C. – Beard, J. L.**: Iron deficiency alters dopamine transporter functioning in rat striatum. *J Nutr*, 2000, 130, s. 2831–2837.
24 **Atis, G. – Dalklinic, A. – Altuntas, Y., et al.**: Sexual dysfunction in women with clinical hypothyroidism and subclinical hypothyroidism. *J Sex Med*, 2010, 7, s. 2583–2590.
25 **Gulmez, H. – Akin, Y. – Savas, M., et al.**: Impact of iron supplementation on sexual dysfunction of women with iron deficiency anemia in short term: a preliminary study. *J Sex Med*, 2014, 11, s. 1042–1046.

Hyperemesis gravidarum – nové poznatky i nové naděje

MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha

1 ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy. *Obstet Gynecol*, 2018.
2 **Singh, D. – Asokan, V. – Gayathri Bhat, N. V., et al.**: Effects of Bilwa-Lajadi syrup in emesis gravidarum – an exploratory single arm open labeled trial. *J Ayurveda Integr Med*, 2022, 13, 100522.
3 **Hinkle, S. N. – Mumford, S. L. – Grantz, K. L., et al.**: Association of nausea and vomiting during pregnancy with pregnancy loss: a secondary analysis of a randomized clinical trial. *JAMA Intern Med*, 2016, 176, s. 1621–1627.
4 **Naeimi Rad, M. – Lamyian, M. – Heshmat, R., et al.**: A randomized clinical trial of the efficacy of KID21 Point (Youmen) acupressure on nausea and vomiting of pregnancy. *Iran Red Crescent Med J*, 2012, 14, s. 697–701.
5 **Matthews, A. – Haas, D. M. – O'Mathúna, D. P., et al.**: Interventions for nausea and vomiting in early pregnancy. *Cochrane Database Syst Rev*, 2015, 2015, CD007575.
6 **Thakur, M. – Gautam, J. – Dangal, G., et al.**: Severity of hyperemesis gravidarum and associated maternal factors. *J Nepal Health Res Counc*, 2019, 17, s. 293–296.
7 **Heinrichs, L.**: Linking olfaction with nausea and vomiting of pregnancy, recurrent abortion, hyperemesis gravidarum, and migraine headache. *Am J Obstet Gynecol*, 2002, 186, s. S215–S219.
8 **Basso, O. – Olsen, J.**: Sex ratio and twinning in women with hyperemesis or pre-eclampsia. *Epidemiology*, 2001, 12, s. 747–749.
9 **Brandes, J. M.**: First-trimester nausea and vomiting as related to outcome of pregnancy. *Obstet Gynecol*, 1967, 30, s. 427–431.
10 **Hou, J. L. – Wan, X. R. – Xiang, Y., et al.**: Changes of clinical features in hydatidiform mole: analysis of 113 cases. *J Reprod Med*, 2008, 53, s. 629–633.
11 **Cardaropoli, S. – Rolfo, A. – Todros, T.**: Helicobacter pylori and pregnancy-related disorders. *World J Gastroenterol*, 2014, 20, s. 654–664.
12 **Kimura, M. – Amino, N. – Tamaki, H., et al.**: Gestational thyrotoxicosis and hyperemesis gravidarum: possible role of hCG with higher stimulating activity. *Clin Endocrinol*, 1993, 38, s. 345–350.
13 **Akdemir, N. – Bilir, C.**: Thyroid dysfunction in hyperemesis gravidarum: a study in Turkish pregnant women. *J Turk Ger Gynecol Assoc*, 2011, 12, s. 140–143.
14 **Shigemi, D. – Nakanishi, K. – Miyazaki, M., et al.**: A case of maternal vitamin K deficiency associated with hyperemesis gravidarum: its potential impact on fetal blood coagulability. *J Nippon Med Sch*, 2015, 82, s. 54–58.
15 **Goodwin, T. M.**: Hyperemesis gravidarum. *Clin Obstet Gynecol*, 1998, 41, s. 597–605.
16 **Jansen, L. A. W. – Koot, M. H. – Van't Hooft, J., et al.**: The windsor definition for hyperemesis gravidarum: A multistakeholder international consensus definition. *Eur J Obstet Gynecol Reprod Biol*, 2021, 266, s. 15–22.
17 **Newman, V. – Fullerton, J. T. – Anderson, P. O.**: Clinical advances in the management of severe nausea and vomiting during pregnancy. *J Obstet Gynecol Neonatal Nurs*, 1993, 22, s. 483–490.
18 **Boelig, R. C. – Barton, S. J. – Saccone, G., et al.**: Interventions for treating hyperemesis gravidarum: a Cochrane systematic review and meta-analysis. *J Matern Fetal Neonatal Med*, 2018, 31, s. 2492–2505.
19 **Koren, G. – Hankins, G. D. – Clark, S., et al.**: Effectiveness of doxylamine-pyridoxine for morning sickness. *Am J Obstet Gynecol*, 2016, 214, s. 664–666.
20 **Majumdar, S. – Dada, B.**: Refeeding syndrome: a serious and potentially life-threatening complication of severe hyperemesis gravidarum. *J Obstet Gynaecol*, 2010, 30, s. 416–417.
21 **Nulman, I. – Rovet, J. – Barrera, M., et al.**: Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and diclectin. *J Pediatr*, 2009, 155, s. 45–50.
22 **Dodds, L. – Fell, D. B. – Joseph, K. S., et al.**: Outcomes of pregnancies complicated by hyperemesis gravidarum. *Obstet Gynecol*, 2006, 107, s. 285–292.
23 **Trogstad, L. I. – Stoltenberg, C. – Magnus, P., et al.**: Recurrence risk in hyperemesis gravidarum. *BJOG*, 2005, 112, s. 1641–1645.
24 **Fejzo, M. S. – Macgibbon, K. W. – Romero, R., et al.**: Recurrence risk of hyperemesis gravidarum. *J Midwifery Womens Health*, 2011, 56, s. 132–136.
25 **Emelianova, S. – Mazzotta, P. – Einarson, A., et al.**: Prevalence and severity of nausea and vomiting of pregnancy and effect of vitamin supplementation. *Clin Invest Med*, 1999, 22, s. 106–110.
26 **Gill, S. K. – Maltepe, C. – Koren, G.**: The effect of heartburn and acid reflux on the severity of nausea and vomiting of pregnancy. *Can J Gastroenterol*, 2009, 23, s. 270–272.

Indukce porodu navozená misoprostolem

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

1 **Tsakiridis, I. – Mamopoulos, A. – Athanasiadis, A., et al.**: Induction of labor: an overview of guidelines. *Obstet Gynecol Surv*, 2020, 75, s. 61–72.
2 ACOG Practice Bulletin No. 107: Induction of labor. *Obstet Gynecol*, 2009, 114, s. 386–397.
3 **Marconi, A. M.**: Recent advances in the induction of labor. *F1000 Res*, 2019, 8.
4 **Alfirevic, Z. – Keeney, E. – Dowswell, T., et al.**: Labour induction with prostaglandins: a systematic review and network meta-analysis. *BMJ*, 2015, 350, s. h217.
5 **Pierce, S. – Bakker, R. – Myers, D. A. et al.**: Clinical insights for cervical ripening and labor induction using prostaglandins. *AJP Rep*, 2018, 8, s. e307–e314.
6 **Yount, S. M. – Lassiter, N.**: The pharmacology of prostaglandins for induction of labor. *J Midwifery Womens Health*, 2013, 58, s. 133–144.
7 **Khan, R. U. – El-Refaey, H. – Sharma, S., et al.**: Oral, rectal, and vaginal pharmacokinetics of misoprostol. *Obstet Gynecol*, 2004, 103, s. 866–870.
8 **Berard, V. – Fiala, C. – Cameron, S., et al.**: Instability of misoprostol tablets stored outside the blister: a potential serious concern for clinical outcome in medical abortion. *PLoS One*, 2014, 9, e112401.
9 **Kerr, R. S. – Kumar, N. – Williams, M. J. – Cuthbert, A., et al.**: Low-dose oral misoprostol for induction of labour. *Cochrane Database Syst Rev*, 2021, 6, CD014484.
10 ANSM. Information relative à l'offre thérapeutique en gynécologie suite à l'arrêt de commercialisation de Cytotec (misoprostol). Dostupné z: https://ansm.sante.fr/actualites/information-relative-a-loffre-therapeutique-en-gynecologie-suite-a-larret-de-commercialisation-de-cytotec-misoprostol, vyhledáno 8. 2. 2024.
11 **Casassus, B.**: Misoprostol drug to be withdrawn from French market. *Lancet*, 2017, 390, s. e42.
12 BfArM. Cytotec (Misoprostol): Risiken im Zusammenhang mit einer Anwendung zur Geburtseinleitung außerhalb der Zulassung („off-label-use"). 2020. Dostupné z: https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/EN/RHB/2020/rhb-cytotec.pdf?__blob=publicationFile, vyhledáno 8. 2. 2024.
13 **Pambet, M. – Delabaere, A. – Figuier, C., et al.**: Factors of non-compliance with a protocol for oral administration of misoprostol (Angusta®) 25 micrograms to induce labor: an observational study. *J Clin Med*, 2023, 12, s. 1521.

Saturace kalciem a vitaminem D: doporučení pro prevenci a léčbu osteoporózy v klinické praxi

MUDr. Jiří Jenšovský, CSc. Interní klinika 1. LF UK a ÚVN – Vojenské fakultní nemocnice Praha

1 **Palička V. – Rosa, J. – Pikner, R. – Býma, S.**: Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře – Osteoporóza. Novelizace 2023. Centrum doporučených postupů pro praktické lékaře. Společnost všeobecného lékařství ČLS JEP, Praha, s. 3–20. Dostupné z: https://www.svl.cz/doporucene-postupy/osteoporoza-100045, vyhledáno 11. 3. 2024.
2 **Pikner, R.**: Optimální příjem vápníku a vitaminu D. In: Džupa, V. – Jenšovský, J. (ed.): *Diagnostika a léčba osteoporózy a dalších onemocnění skeletu*. Praha, Karolinum, 2018, s. 187–192.
3 **Heaney, R. P. – Recker, R. R. – Stegman, M. R., et al.**: Calcium absorption in women. *J Bone Miner Res*, 1989, 4, s. 469–475.
4 **Holick, M. F. – Matsuoka, L. Y. – Wortsman, J.**: Age, vitamin D and solar ultraviolet radiation. *Lancet*, 1989, 2, s. 1104–1105.
5 **Holick, M. F.**: Vitamin D: new horizons for 21st century. *Am J Clin Nutr*, 1994, 2, s. 619–630.
6 **Malaban, A. – Veronikis, I. E. – Holick, M. F.**: Redefining vitamin D deficiency. *Lancet*, 1998, 351, s. 805–806.
7 **Selinger, E. – Neuenschwander, M. – Koller, A., et al.**: Evidence of vegan diet for health benefits and risks – an umbrelle review of meta-analyses of observational and clinical studies. *Critical Reviews in Food Science and Nutrition*, 2023, 63, s. 9926–9936.
8 **Falchetti, A. – Cavati, G. – Valenti, R., et al.**: The effects of vegetarian diets on bone health: A literature review. *Front Endocrinol*, 2022, 13, dostupné z: https://doi.org/10.3389/fendo.2022.899375, vyhledáno

11. 3. 2024.
9 **Li, S. – Mao, Y. – Zhou, F., et al.**: Gut microbiome and osteoporosis. Bone Joint Res, 2020, 9, s. 524–530.
10 **Retterdal, E. – Ilesanmi-Oyelere, B. L. – Roy, N. C., et al.**: The gut microbiome is altered in postmenopausal women with osteoporosis and osteopenia. *JBMR Plus*, 2021, 5, e10452.
11 **Orwoll, E. S. – Parimi, N. – Wiedrick, J., et al.**: Analysis of associations between the human fecal microbiome and bone density, structure and strength. *JBMR*, 2022, 37, s. 597–607.
12 **Xu, Z. – Xie, Z. – Sun, J., et al.**: Gut microbiome reveals specific dysbiosis in primary osteoporosis. *Frontiers in cellular and infection mikrobiology*, 2020, 10, s. 1–11.
13 **Bischoff-Ferrari, H. A. – Dawson- Hughes, B. – Staehelin, H. B., et al.**: Fall prevention with supplemental and active form of vitamin D. *BMJ*, 2009, 339, b3692.
14 **Bischoff-Ferrari, H. A. – Dawson-Hughes, B. – Wallet, W. C., et al.**: Effect of vitamin D on falls. *JAMA*, 2004, s. 1999–2006.
15 **Jenšovský, J.**: Suplementace vitaminem D a kalciem – význam v gynekologii. *Česká gynekologie*, 2020, 5, s. 357–361.

Nehormonální přístupy v managementu genitourinárního menopauzálního syndromu

doc. MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

1 **Nappi, R. E. – Kokot-Kierepa, M.**: Women's voices in the menopause: results from an international survey on vaginal atrophy. *Maturitas*, 2010, 67, s. 233–238.
2 **Bachmann, G. A. – Nevadunsky, N. S.**: Diagnosis and treatment of atrophic vaginitis. *Am Fam Physician*, 2000, 61, s. 3090–3096.
3 The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. *Menopause*, 2020, 27, s. 976–992.
4 **Da Silva, A. S. – Baines, G. – Araklitis, G., et al.**: Modern management of genitourinary syndrome of menopause. *Fac Rev*, 2021, 10, s. 25.
5 **Newson, L. – Kirby, M. – Stillwell, S., et al.**: Position Statement for Management of Genitourinary Syndrome of the Menopause (GSM). BSSM. Dostupné z: https://bssm.org.uk/wp-content/uploads/2023/02/GSM-BSSM.pdf, vyhledáno 8. 5. 2024.
6 **Stute, P. – May, T. W. – Masur, C., et al.**: Efficacy and safety of non-hormonal remedies for vaginal dryness: open, prospective, randomized trial. *Climacteric*, 2015, 18, s. 582–589.
7 **Garcia de Arriba, S. – Grüntkemeier, L., et al.**: Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study. *PLoS One*, 2022, 17, e0266633.
8 **Chatsiproios, D. – Schmidts-Winkler, I. M. – König, L., et al.**: Topical treatment of vaginal dryness with a non-hormonal cream in women undergoing breast cancer treatment – an open prospective multicenter study. *PLoS One*, 2019, 14, e0210967.
9 Eichler, S. – Panz, M. – Harder, A., et al.: An effective non-hormonal option with high tolerability for mild to moderate symptoms of vaginal dryness associated with menopause. *Maturitas*, 2024, 185, 107978.

Výživa a nutriční příprava jako podstatný faktor pooperační morbidity

MUDr. Tomáš Brtnický, Ph.D. | MUDr. Markéta Malecová Gynekologicko-porodnická klinika 1. LF UK a Fakultní nemocnice Bulovka, Praha

1 **Bruun, L. I. – Bosaeus, I. – Bergstad, I., t al.**: Prevalence of malnutrition in surgical patients: evaluation of nutritional support and documentation. *Clin Nutr*, 1999, 18, s. 141–147.
2 **Williams, D. G. A. – Molinger, J. – Wischmeyer, P. E.**: The malnourished surgery patient: a silent epidemic in perioperative outcomes? *Curr Opin Anaesthesiol*, 2019, 32, s. 405–411.
3 **Ligthart-Melis, G. C. – Luiking, Y. C. – Kakourou, A., et al.**: Frailty, sarcopenia, and malnutrition frequently (co-)occur in hospitalized older adults: a systematic review and meta-analysis. *J Am Med Dir Assoc*, 2020, 21, s. 1216–1228.
4 **McWhirter, J. P. – Pennington, C. R.**: Incidence and recognition of malnutrition in hospital. *BMJ*, 1994, 308, s. 945–948.
5 **Correia, M. I. – Waitzberg, D. L.**: The impact of malnutrition on morbidity, mortality, length of hospital stay and costs evaluated through a multivariate model analysis. *Clin Nutr*, 2003, 22, s. 235–239.
6 **Vaid, S. – Bell, T. – Grim, R., et al.**: Predicting risk of death in general surgery patients on the basis of preoperative variables using American College of Surgeons National Surgical Quality Improvement Program data. *Perm J*, 2012, 16, s. 10–17.
7 **Weiss, A. J. – Fingar, K. R. – Barrett, M. L., et al.**: Characteristics of hospital stays involving malnutrition, 2013. 2016. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US), 2006, Statistical Brief #210. PMID: 27854406.
8 **van Bokhorst-de van der Schueren, M. A. – Guaitoli, P. R. – Jansma, E. P. – de Vet, H. C.**: Nutrition screening tools: does one size fit all? A systematic review of screening tools for the hospital setting. *Clin Nutr.* 2014, 33, s. 39–58.
9 **Kondrup, J. – Rasmussen, H. H. – Hamberg, O., et al.**; Ad Hoc ESPEN Working Group: Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. *Clin Nutr*, 2003, 22, s. 321–336.
10 **Bouillanne, O. – Morineau, G. – Dupont, C., et al.**: Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. *Am J Clin Nutr*, 2005, 82, s. 777–783.
11 **Elia, M. (ed.)**: The 'MUST' report. Nutritional screening of adults: a multidisciplinary responsibility 2003. Pp 1–138. Dostupné z: https://www.bapen.org.uk/pdfs/must/must-report.pdf, vyhledáno 10. 4. 2024.
12 **Skipper, A. – Ferguson, M. – Thompson, K., et al.**: Nutrition screening tools: an analysis of the evidence. *JPEN J Parenter Enteral Nutr*, 2012, 36, s. 292–298.
13 **Williams, D. G. – Aronson, S. – Murray, S., et al.**: Validation of the perioperative nutrition screen for prediction of postoperative outcomes. *JPEN J Parenter Enteral Nutr*, 2022, 46, s. 1307–1315.
14 **Cheung, H. H. T. – Joynt, G. M. – Lee, A.**: Diagnostic test accuracy of preoperative nutritional screening tools in adults for malnutrition: a systematic review and network meta-analysis. *Int J Surg*, 2024, 110, s. 1090–1098.
15 **Jain, S. R. – Kandarpa, V. L. – Yaow, C. Y. L., et al.**: The role and effect of multimodal prehabilitation before major abdominal surgery: a systemic review and meta-analysis. *World J Surg*, 2023, 47.1, s. 86–102.
16 **Chocenská, E., et al.**: Doplňky stravy při léčbě onkologických onemocnění. *Interní Med*, 2012, 14, s. 85–86.
17 **Nelson, G. – Bakkum-Gamez, J. – Kalogera, E., et al.**: Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations – 2019 update. *Int J Gynecol Cancer*, 2019, 29, s. 651–668.
18 **Cutillo, G. – Maneschi, F. – Franchi, M., et al.**: Early feeding compared with nasogastric decompression after major oncologic gynecologic surgery: a randomized study. *Obstet Gynecol*, 1999, 93, s. 41–45.
19 **Charoenkwan, K. – Matovinovic, E.**: Early versus delayed oral fluids and food for reducing complications after major abdominal gynaecologic surgery. *Cochrane Database Syst Rev*, 2014, 2014, CD004508.
20 **Minig, L – Biffi, R. – Zanagnolo, V., et al.**: Early oral versus "traditional" postoperative feeding in gynecologic oncology patients undergoing intestinal resection: a randomized controlled trial. *Ann Surg Oncol*, 2009, 16, s. 1660–1668.
21 **Minig, L. – Biffi, R. – Zanagnolo, V., et al.**: Reduction of postoperative complication rate with the use of early oral feeding in gynecologic oncologic patients undergoing a major surgery: a randomized controlled trial. *Ann Surg Oncol*, 2009, 16, s. 3101–3110.
22 **Pearl, M. L. – Valea, F. A. – Fischer, M., et al.**: A randomized controlled trial of early postoperative feeding in gynecologic oncology patients undergoing intra-abdominal surgery. *Obstet Gynecol*, 1998, 92, s. 94–97.
23 **Schilder, J. M. – Hurteau, J. A. – Look, K. Y., et al.**: A prospective controlled trial of early postoperative oral intake following major abdominal gynecologic surgery. *Gynecol Oncol*, 1997, 67, s. 235–240.
24 **Wischmeyer, P. E. – Carli, F. – Evans, D. C., et al.**: American Society for enhanced recovery and perioperative quality initiative joint consensus statement on nutrition screening and therapy within a surgical enhanced recovery pathway. *Anesth Analg*, 2018, 126, s. 1883–1895.
25 **Nelson, G. – Altman, A. D. – Nick, A.**: Guidelines for pre- and intra-operative care in gynecologic/oncology surgery: Enhanced Recovery After Surgery (ERAS®) Society recommendations – Part I. *Gynecol Oncol*, 2016, 140, s. 313–322.
26 **Kohout, P., et al.**: *Klinická výživa*. Praha, Galén, 2021, s. 865–871.
27 **Weimann, A. – Braga, M. – Carli, F., et al.**: ESPEN guideline: Clinical nutrition in surgery. *Clin Nutr*, 2017, 36, s. 623–650.
28 **Yeung, S. E. – Hilkewich, L. – Gillis, C., et al.**: Protein intakes are associated with reduced length of stay: a comparison between Enhanced Recovery After Surgery (ERAS) and conventional care after elective colorectal surgery. *Am J Clin Nutr*, 2017, 106, s. 44–51.
29 **McClave, S. A. – Taylor, B. E. – Martindale, R. G., et al.**; Society of Critical Care Medicine; American Society for Parenteral and Enteral Nutrition: Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). *J Parenter Enteral Nutr*, 2016, 40, s. 159–211.
30 **Stechmiller, J. K.**: Understanding the role of nutrition and wound healing. *Nutr Clin Pract*, 2010, 25, s. 61–68.

První studie mapující život pacientů s chronickým únavovým syndromem v České republice

1 Centers for Disease Control and Prevention. Presentation and Clinical Course of ME/CFS. Dostupné z: https://www.cdc.gov/me-cfs/healthcare-providers/presentation-clinical-course/ epidemiology.html, vyhledáno 10. 5. 2024.
2 Myalgic encephalomyelitis and Chronic Fatigue Syndrome (ME/CFS): A systematic review. Stockholm: Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU); 2018 Dec 20. (SBU Policy support, No. 295.) Dostupné z: https://www.ncbi.nlm.nih.gov/books/NBK570660/, vyhledáno 10. 5. 2024.
3 National Institute for Health and Care Excellence: NICE outlines steps needed to put ME/CFS guideline into practice. 2022. Dostupné z: https://www.nice.org.uk/news/article/nice-outlines-steps-needed-to-put-me- cfs-guideline-into-practice, vyhledáno 10. 5. 2024.
4 **Twisk, F.**: Dutch Health Council Advisory Report on myalgic encephalomyelitis and chronic fatigue syndrome: Taking the wrong turn. *Diagnostics*, 2018, 8, s. 34. Dostupné z: https://doi.org/10.3390/diagnostics8020034, vyhledáno 10. 5. 2024.
5 What is ME/CFS? Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a life-altering multi-system chronic, complex disease (msCCD). Open Medicine Foundation. Dostupné z: https://www.omf.ngo/what-is-mecfs/, vyhledáno 10. 5. 2024.
6 Request for funding for biomedical research on Myalgic Encephalomyelitis. European Parliament resolution of 18 June 2020 on additional funding for biomedical research on Myalgic Encephalomyelitis (2020/2580(RSP). Dostupné z: https://www.europarl.europa.eu/doceo/document/ TA-9-2020-0140_EN.pdf, vyhledáno 10. 5. 2024.